Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q1 2023 · 10-Q
Revenue$9.85M$9.85M+45.5% vs Q1 2022 Net Income-$49.04M-$49.04MN/M vs Q1 2022 EPS Diluted-$0.71-$0.71N/M vs Q1 2022 Operating Income-$50,961,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
Free Cash Flowderived-$37,608,000N/M Margins · derivedOperating margin-517.3%+232.2 pt vs Q1 2022
Net margin-497.8%+248.3 pt vs Q1 2022
ended Mar 31, 2023 · filed May 5, 2023 · 35 d after period end